Clinical Trial Update: Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 [Phase 2]

View source ↗

Summary

A Phase 2 trial completed evaluating in vivo azacitidine incorporation in mononuclear cells after Vidaza or CC-486 treatment in patients with myelodysplastic sy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• CC-486 (azacitidine)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Kirby Institute | Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED